NEWS
Our Latest News
ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions
Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.
ARCHIMED buys Cube, an innovative provider of membrane protein services for the biopharma research market
November
3,
2021
ARCHIMED refinances Ad-Tech less than a year after purchase, returning more than a third of investment to shareholders
October
20,
2021
ARCHIMED’s NAMSA returns more than a third of investment
October
7,
2021
368